Skip Navigation



Annals of Oncology Advance Access published online on September 4, 2007
Annals of Oncology, doi:10.1093/annonc/mdm399
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/1/92    most recent
mdm399v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Van Cutsem, E
Right arrow Articles by Peeters, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Cutsem, E
Right arrow Articles by Peeters, M
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy

E Van Cutsem1,*, S Siena2, Y Humblet3, J-L Canon4, J Maurel5, E Bajetta6, B Neyns7, D Kotasek8, A Santoro9, W Scheithauer10, S Spadafora11, RG Amado12, N Hogan13 and M Peeters14

1 Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
2 Divisione Oncologia Falck, Ospedale Niguarda Cá Granda, Milan, Italy
3 Department of Medical Oncology, St-Luc University Hospital, Universite Catholique de Louvain, Brussels, Belgium
4 Department of Oncology-Hematology, Centre Hospitalier Notre Dame et Reine Fabiola, Charleroi, Belgium
5 Medical Oncology Service, Hospital Clinic de Barcelona, Ciberehd, Barcelona, Spain
6 Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
7 Kliniekhoofd Medische Oncologie, Oncologisch Centrum, UZ Brussel, Brussels, Belgium
8 Medical Oncology, Ashford Cancer Centre, Ashford, Australia
9 Department of Gastroenterology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
10 Department of Internal Medicine I and Cancer Center, Medical University of Vienna, Vienna, Austria
11 Algoma District Cancer Program at Sault Area Hospital, Sault Sainte Marie, Ontario, Canada
12 Clinical Development, Amgen Inc ,Thousand Oaks, CA, USA
13 Medical Affairs Biostatistics, Amgen Ltd, Cambridge, UK
14 HepatoGastroenterology, Digestive Oncology Unit, Ghent University Hospital, Ghent, Belgium

* Correspondence to: Prof. E. Van Cutsem, University Hospital Gasthuisberg, 3000 Leuven, Belgium. Tel: +32-16-344218; Fax: +32-16-344419; E-mail: eric.vancutsem{at}uz.kuleuven.ac.be

Background: A phase 3 study demonstrated that panitumumab, a human monoclonal anti-epidermal growth factor receptor antibody, significantly prolonged progression-free survival versus best supportive care (BSC) in patients with chemorefractory metastatic colorectal cancer.

Patients and methods: This open-label extension study evaluated panitumumab monotherapy in BSC patients with radiographically documented disease progression in the phase 3 study. Patients received panitumumab 6 mg/kg every 2 weeks. The primary end point was safety; efficacy was also evaluated.

Results: One hundred and seventy-six patients were randomly assigned to the BSC arm of the phase 3 study received ≥1 panitumumab dose in this extension study. Panitumumab was well tolerated. The most frequent treatment-related adverse events were skin toxic effects. Three (2%) patients had a grade 4 treatment-related adverse event. There were no infusion reactions. One (0.6%) patient had a complete response; 19 (11%) patients had a partial response; and 58 (33%) patients had stable disease. Median progression-free survival time was 9.4 [95% confidence interval (CI): 8.0–13.4) weeks. Median overall survival time was 6.3 (95% CI: 5.1–6.8) months. Anti-panitumumab antibodies were detected in 3 (4.2%) of 71 patients with a post-baseline sample.

Conclusions: These findings are comparable to those from the phase 3 study and support panitumumab monotherapy for chemorefractory colorectal cancer.

crossover, EGFr, extension study, fully human antibody, metastatic colorectal cancer, panitumumab

Received for publication April 1, 2007. Revision received July 10, 2007. Accepted for publication July 11, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
K. Muro, T. Yoshino, T. Doi, K. Shirao, H. Takiuchi, Y. Hamamoto, H. Watanabe, B.-B. Yang, and D. Asahi
A Phase 2 Clinical Trial of Panitumumab Monotherapy in Japanese Patients with Metastatic Colorectal Cancer
Jpn. J. Clin. Oncol., May 1, 2009; 39(5): 321 - 326.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Peeters, T. Price, and J.-L. Van Laethem
Anti-Epidermal Growth Factor Receptor Monotherapy in the Treatment of Metastatic Colorectal Cancer: Where Are We Today?
Oncologist, January 1, 2009; 14(1): 29 - 39.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Di Nicolantonio, M. Martini, F. Molinari, A. Sartore-Bianchi, S. Arena, P. Saletti, S. De Dosso, L. Mazzucchelli, M. Frattini, S. Siena, et al.
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
J. Clin. Oncol., December 10, 2008; 26(35): 5705 - 5712.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.